Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.7
(13.0%)
USD 1.7
(13.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 406.16 Million USD | 60.07% |
| 2021 | 253.73 Million USD | 0.21% |
| 2020 | 253.19 Million USD | -0.54% |
| 2019 | 254.55 Million USD | 6.69% |
| 2018 | 238.6 Million USD | -11.65% |
| 2017 | 270.06 Million USD | 26.45% |
| 2016 | 213.57 Million USD | 71.4% |
| 2015 | 124.6 Million USD | 133.29% |
| 2014 | 53.41 Million USD | 195.05% |
| 2013 | 18.1 Million USD | 91.8% |
| 2012 | 9.43 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 404.82 Million USD | -2.26% |
| 2023 Q1 | 414.17 Million USD | 1.97% |
| 2022 Q4 | 406.16 Million USD | 4.13% |
| 2022 Q2 | 381.75 Million USD | 19.24% |
| 2022 Q3 | 390.06 Million USD | 2.18% |
| 2022 FY | 406.16 Million USD | 60.07% |
| 2022 Q1 | 320.16 Million USD | 26.18% |
| 2021 Q4 | 253.73 Million USD | -0.99% |
| 2021 Q1 | 259.96 Million USD | 2.68% |
| 2021 FY | 253.73 Million USD | 0.21% |
| 2021 Q3 | 256.26 Million USD | -3.02% |
| 2021 Q2 | 264.24 Million USD | 1.64% |
| 2020 Q3 | 248.16 Million USD | -3.33% |
| 2020 Q1 | 361.94 Million USD | 42.19% |
| 2020 Q2 | 256.71 Million USD | -29.07% |
| 2020 Q4 | 253.19 Million USD | 2.03% |
| 2020 FY | 253.19 Million USD | -0.54% |
| 2019 Q3 | 257.03 Million USD | -1.76% |
| 2019 FY | 254.55 Million USD | 6.69% |
| 2019 Q4 | 254.55 Million USD | -0.97% |
| 2019 Q2 | 261.63 Million USD | 0.84% |
| 2019 Q1 | 259.45 Million USD | 8.74% |
| 2018 Q2 | 273.93 Million USD | 9.88% |
| 2018 Q1 | 249.29 Million USD | -7.69% |
| 2018 FY | 238.6 Million USD | -11.65% |
| 2018 Q4 | 238.6 Million USD | -11.23% |
| 2018 Q3 | 268.78 Million USD | -1.88% |
| 2017 Q1 | 224.82 Million USD | 5.27% |
| 2017 Q2 | 220.17 Million USD | -2.06% |
| 2017 Q3 | 266.89 Million USD | 21.22% |
| 2017 Q4 | 270.06 Million USD | 1.19% |
| 2017 FY | 270.06 Million USD | 26.45% |
| 2016 Q2 | 149.36 Million USD | 16.06% |
| 2016 FY | 213.57 Million USD | 71.4% |
| 2016 Q3 | 146.72 Million USD | -1.77% |
| 2016 Q4 | 213.57 Million USD | 45.56% |
| 2016 Q1 | 128.7 Million USD | 3.29% |
| 2015 Q2 | 121.02 Million USD | -6.85% |
| 2015 Q4 | 124.6 Million USD | 1.95% |
| 2015 Q3 | 122.21 Million USD | 0.98% |
| 2015 Q1 | 129.93 Million USD | 159.38% |
| 2015 FY | 124.6 Million USD | 133.29% |
| 2014 Q4 | 50.09 Million USD | -6.21% |
| 2014 Q1 | 63.95 Million USD | 255.11% |
| 2014 FY | 53.41 Million USD | 195.05% |
| 2014 Q2 | 58.15 Million USD | -9.06% |
| 2014 Q3 | 53.41 Million USD | -8.16% |
| 2013 Q2 | 15.75 Million USD | 0.0% |
| 2013 Q3 | 18.1 Million USD | 14.91% |
| 2013 FY | 18.1 Million USD | 91.8% |
| 2013 Q4 | 18.01 Million USD | -0.51% |
| 2012 Q4 | - USD | -100.0% |
| 2012 FY | 9.43 Million USD | 0.0% |
| 2012 Q3 | 9.43 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 55.092% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -607.374% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 64.475% |
| Cosmos Health Inc. | 66.29 Million USD | -512.65% |
| Dynavax Technologies Corporation | 997.09 Million USD | 59.266% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 44.231% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 74.202% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -1385.211% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -1385.211% |
| SCYNEXIS, Inc. | 128.41 Million USD | -216.294% |
| Safety Shot Inc | 12.7 Million USD | -3095.8% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -1656.211% |
| Alpha Teknova, Inc. | 128.58 Million USD | -215.864% |
| Bright Green Corporation | 17.4 Million USD | -2233.844% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -97.36% |
| Embecta Corp. | 1.21 Billion USD | 66.555% |
| PainReform Ltd. | 9.93 Million USD | -3990.232% |
| Journey Medical Corporation | 76.84 Million USD | -428.517% |
| Procaps Group, S.A. | 460.18 Million USD | 11.74% |
| Theratechnologies Inc. | 77.76 Million USD | -422.265% |
| Harrow Health, Inc. | 311.75 Million USD | -30.282% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -2627.187% |
| Biofrontera Inc. | 27.93 Million USD | -1354.103% |
| DURECT Corporation | 45.18 Million USD | -798.803% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 71.173% |
| Cronos Group Inc. | 1.13 Billion USD | 64.191% |
| OptiNose, Inc. | 107.72 Million USD | -277.02% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 13.78% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -625.947% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -1662.301% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 11.709% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -3307.904% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -396.673% |
| Radius Health, Inc. | 1.71 Billion USD | 76.33% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -662.212% |
| ProPhase Labs, Inc. | 91.92 Million USD | -341.829% |
| Phibro Animal Health Corporation | 982.18 Million USD | 58.647% |
| Procaps Group S.A. | 460.18 Million USD | 11.74% |
| Alvotech | 950.09 Million USD | 57.25% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -837.819% |
| Viatris Inc. | 47.68 Billion USD | 99.148% |
| Rockwell Medical, Inc. | 52.17 Million USD | -678.487% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -243.926% |
| SIGA Technologies, Inc. | 254.83 Million USD | -59.381% |
| Tilray Brands, Inc. | 4.33 Billion USD | 90.631% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -48.395% |
| Shineco, Inc. | 84.17 Million USD | -382.493% |
| PetIQ, Inc. | 868.22 Million USD | 53.22% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -4713.343% |
| Incannex Healthcare Limited | 17.04 Million USD | -2282.589% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 87.508% |
| Alimera Sciences, Inc. | 153.52 Million USD | -164.558% |
| Silver Spike Investment Corp. | 88.57 Million USD | -358.543% |
| Assertio Holdings, Inc. | 286.41 Million USD | -41.806% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -6724.227% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -1101.806% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -1200.003% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -2965.928% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -55.542% |
| Hempacco Co., Inc. | 18.04 Million USD | -2151.057% |
| Talphera, Inc. | 20.39 Million USD | -1891.468% |
| Alvotech | 950.09 Million USD | 57.25% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 75.401% |
| Currenc Group, Inc. | 141.49 Million USD | -187.058% |
| Kamada Ltd. | 351.96 Million USD | -15.396% |
| Indivior PLC | 1.95 Billion USD | 79.185% |
| Evoke Pharma, Inc. | 7.06 Million USD | -5646.019% |
| Flora Growth Corp. | 23.62 Million USD | -1619.123% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -2965.928% |
| Evolus, Inc. | 188.99 Million USD | -114.902% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 68.263% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 73.154% |
| Akanda Corp. | 8.83 Million USD | -4494.574% |